Treatment for Adenoviral Conjunctivitis
Adenoviral conjunctivitis is self-limited with no proven cure, but symptomatic treatment with artificial tears, cold compresses, and topical antihistamines is recommended for most cases, while topical corticosteroids should be reserved only for severe cases with marked chemosis, epithelial sloughing, or membranous conjunctivitis 1.
Key Management Principles
Avoid Antibiotics
Antibiotics should NOT be used in adenoviral conjunctivitis due to potential adverse effects without any benefit, as this is a viral infection 1.
Standard Symptomatic Treatment
For uncomplicated cases, the following provide symptom relief:
- Artificial tears (lubricating drops)
- Cold compresses
- Topical antihistamines
- Oral analgesics for pain 1
When to Use Topical Corticosteroids
Reserve topical steroids for severe presentations only, specifically when patients have 1:
- Marked chemosis or eyelid swelling
- Epithelial sloughing
- Membranous conjunctivitis
Important caveats about steroid use:
- Animal studies show prolonged viral shedding with corticosteroids (unknown if this occurs in humans) 1
- Requires close follow-up with IOP monitoring and pupillary dilation checks for glaucoma and cataract 1
- Use minimum effective dose and taper slowly once inflammation controlled 1
- Consider safer options like fluorometholone or loteprednol (less IOP elevation risk) 1
Emerging Treatment Options
Povidone-iodine (PVP-I) has shown promise in recent studies:
- The most recent 2026 study found that combination therapy with PVP-I 1% + ganciclovir 0.15% + dexamethasone 0.1% significantly reduced symptom severity and decreased subepithelial infiltrates and pseudomembranes 2
- PVP-I 0.6-1% four times daily for 5-7 days appears safe and well-tolerated 3
- However, the 2024 AAO guidelines note PVP-I is still under investigation 1
Topical ganciclovir 0.15% gel (off-label):
- Shows potential benefit against specific adenovirus serotypes 1
- Needs larger-scale efficacy studies before definitive recommendations 1
- The 2026 study supports its use in combination therapy 2
Management of Complications
For subepithelial infiltrates (develop 1+ weeks after onset) 1:
- Mild cases: observation only
- Symptomatic cases (blurring, photophobia, decreased vision): topical corticosteroids at minimum effective dose
- Alternative: cyclosporine 0.05% to 1% drops
For membranous conjunctivitis:
- Consider membrane debridement to prevent corneal abrasions or permanent cicatricial changes 1
Follow-Up Schedule
- Severe disease (corneal ulceration, membranes): re-evaluate within 1 week 1
- Patients on steroids: regular monitoring of IOP and lens status 1
- Patients not on steroids: return if symptoms persist beyond 2-3 weeks 1
Critical Infection Control
Patients are contagious for 10-14 days from symptom onset in the last affected eye 1:
- Frequent handwashing with soap and water (not just sanitizer)
- Separate towels and pillows
- Avoid close contact, especially for healthcare workers and food service employees
- The virus survives on surfaces for weeks 1
Clinical Pitfall
While recent research (2026) suggests combination therapy with PVP-I, ganciclovir, and dexamethasone may be superior 2, the 2024 AAO Preferred Practice Pattern guidelines remain conservative, stating there is "no proven effective treatment for eradication" and that these agents need further study 1. In real-world practice, symptomatic treatment remains the standard, with judicious steroid use only for severe cases requiring close monitoring.